IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0326806.html
   My bibliography  Save this article

Economic assessment of potential changes to essential medicines for diabetes in Uganda

Author

Listed:
  • Atousa Bonyani
  • Tracy K Lin
  • Ambrose Jakira
  • Isaac D Kimera
  • Martin Muddu
  • Jeremy I Schwartz
  • James G Kahn

Abstract

Background: The World Health Organization suggests selecting essential medicines based on availability, accessibility, affordability, cost-effectiveness, and safety and efficacy. We examined Oral Hypoglycemic Agents (OHAs) for type 2 diabetes mellitus in the Essential Medicines and Health Supplies List for Uganda (EMHSLU), assessed all criteria, and proposed alternative medicines to improve cost-savings and health outcomes. Methods: We conducted a literature review followed by budget impact analysis (BIA) to evaluate potential cost-savings from refining EMHSLU. In our literature review, we identified metrics for measuring availability, accessibility, and affordability of medicines and evaluated evidence on cost-effectiveness, safety, and efficacy of OHAs. According to the country context and available data, we used applicable methods to analyze five classes of OHAs available in Uganda. Since the government covers essential medicines in the public sector based on BIA, we assessed affordability for the government by examining potential savings in two scenarios (#1: shifts within the EMHSLU; #2: use of non-EMHSLU drugs). Results: OHAs added to the EMHSLU 2023 are less available and accessible compared to OHAs in EMHSLU 2016. BIA scenario 1 revealed that the complete replacement of glimepiride 2 mg and gliclazide 80 mg with glibenclamide 5 mg could save the government up to USD 2.65 million per year. Additionally, scenario 2 showed that full replacement of dapagliflozin 10 mg and glimepiride 4 mg instead of their lower doses can save up to United States Dollar (USD) 230,000 and USD 600,000 per year, respectively. A review and adaptation of a published cost-effectiveness analysis highlights that sitagliptin is a cost-effective OHA in Uganda with an estimated Incremental Cost Effectiveness Ratio of $6,132/Quality-Adjusted LifeYear. Conclusion: The findings suggest several potential type 2 diabetes oral medication substitutions which would reduce costs.

Suggested Citation

  • Atousa Bonyani & Tracy K Lin & Ambrose Jakira & Isaac D Kimera & Martin Muddu & Jeremy I Schwartz & James G Kahn, 2025. "Economic assessment of potential changes to essential medicines for diabetes in Uganda," PLOS ONE, Public Library of Science, vol. 20(6), pages 1-19, June.
    • Handle: RePEc:plo:pone00:0326806
    DOI: 10.1371/journal.pone.0326806
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0326806
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0326806&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0326806?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0326806. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.